Benefit of losartan/hydrochlorothiazide-fixed dose combination treatment for isolated morning hypertension: The MAPPY...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Morning hypertension is a significant risk factor for cardiovascular events.
• Effective management of morning blood pressure (BP) is crucial for hypertensive patients.

Purpose of the Study:

• To evaluate the efficacy of a 50-mg losartan/12.5-mg hydrochlorothiazide (Los/HCTZ) combination versus 100-mg losartan (High-Los) in controlling isolated and sustained morning hypertension.
• To compare the effectiveness of Los/HCTZ and High-Los in achieving controlled BP levels in patients with different types of morning hypertension.

Main Methods:

• Sub-analysis of the Morning Hypertension and Angiotensin Receptor Blocker/Hydrochlorothiazide Combination Therapy (MAPPY) study.
• Patients with treated morning hypertension were randomized to receive either Los/HCTZ or High-Los for 3 months.
• Blood pressure was monitored to classify patients into isolated morning hypertension or sustained hypertension groups.

Main Results:

• Los/HCTZ demonstrated superior control of isolated morning hypertension, with 81.8% of patients achieving controlled BP compared to 21.4% with High-Los (p = 0.003).
• For sustained hypertension, Los/HCTZ also showed better control rates (47.7%) than High-Los (31.7%), with significant achievement of systolic BP < 135 mmHg (p = 0.022).
• Los/HCTZ was significantly more effective than High-Los in treating both isolated and sustained morning hypertension.

Conclusions:

• The Los/HCTZ combination is an effective treatment for controlling both isolated and sustained morning hypertension.
• Los/HCTZ offers a superior therapeutic option compared to high-dose losartan for managing morning hypertension.
• Targeted treatment with Los/HCTZ can significantly improve BP control in patients experiencing morning hypertension.